ProMIS Neurosciences to Present at Extraordinary Futures Investment Conference
TORONTO and CAMBRIDGE, MA, Sept. 17, 2018 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced that it will be featured as a presenting company at the Extraordinary Futures Investment Conference, sponsored by Cambridge House. The conference is being held on September 19-20, 2018 at the Vancouver Convention Centre East in Vancouver, British Columbia.
Elliot Goldstein, President & CEO of ProMIS Neurosciences will provide a corporate overview in the Workshop 1 room on Thursday, September 20, 2018, at 12:50 p.m. PT, and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. ProMIS will also be hosting a booth at the conference.
If you are an investor and would like to attend the Company's presentation please visit https://cambridgehouse.com/register/74 to register for the conference.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform -ProMIS™ and Collective Coordinates- to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
For more information please visit us at: www.promisneurosciences.com
SOURCE ProMIS Neurosciences Inc.
For further information:
For media inquiries, please contact: Shanti Skiffington, firstname.lastname@example.org, Tel. 617 921-0808; For Investor Relations please contact: Alpine Equity Advisors, Nicholas Rigopulos, President, email@example.com, Tel. 617 901-0785; Dr. Elliot Goldstein, President and Chief Executive Officer, ProMIS Neurosciences Inc., Tel. 415 341-5783, Elliot.firstname.lastname@example.org